Amicus Therapeutics Inc (FOLD)

10.44
NASDAQ : Health Care
Prev Close 10.09
Day Low/High 9.93 / 10.47
52 Wk Low/High 4.41 / 10.47
Avg Volume 2.51M
Exchange NASDAQ
Shares Outstanding 142.92M
Market Cap 1.44B
EPS -1.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Keep Biotech Trigger Fingers Holstered

Keep Biotech Trigger Fingers Holstered

Three names show how fast biotechs can become oversold when the market acts in knee-jerk fashion.

Biotech Movers: Ionis, Alnylam, Amicus, Minerva

Biotech Movers: Ionis, Alnylam, Amicus, Minerva

Ionis Pharmaceuticals, Alnylam Pharmaceuticals, Amicus Therapeutics and Minerva Neurosciences were among the biotech movers in premarket trading on Monday.

Amicus Therapeutics (FOLD) Shares Cross Below 200 DMA

In trading on Monday, shares of Amicus Therapeutics Inc crossed below their 200 day moving average of $6.78, changing hands as low as $6.73 per share. Amicus Therapeutics Inc shares are currently trading down about 1.7% on the day.

Vegas Baby: Rolling '777s' in Biotech

Vegas Baby: Rolling '777s' in Biotech

Three small-cap biotechs with attractive risk/reward profiles.

Interesting FOLD Put And Call Options For May 19th

Investors in Amicus Therapeutics Inc saw new options become available this week, for the May 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the FOLD options chain for the new May 19th contracts and identified one put and one call contract of particular interest.

Amicus Therapeutics Launches Galafold™ (Migalastat) For Treatment Of Fabry Disease In Italy

Ministry of Health Publishes Final Guidance Covering Reimbursement of Galafold for Fabry Disease

Amicus CEO John Crowley, Not His Daughter Megan, Might Compel Trump to Make Big Changes at FDA

Amicus CEO John Crowley, Not His Daughter Megan, Might Compel Trump to Make Big Changes at FDA

Absent specific policy details, Trump's speech leaves investors guessing about his real plans for the FDA and the drug approval process. He has not yet named an FDA commissioner.

Short Interest In Amicus Therapeutics Jumps 14%

The most recent short interest data has been released for the 01/31/2017 settlement date, which shows a 4,046,337 share increase in total short interest for Amicus Therapeutics Inc , to 32,785,226, an increase of 14.08% since 01/13/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Interesting FOLD Call Options For February 17th

Investors in Amicus Therapeutics Inc saw new options become available this week, for the February 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the FOLD options chain for the new February 17th contracts and identified the following call contract of particular interest.

7 Things to Watch in Biotech Now

7 Things to Watch in Biotech Now

M&A, drug approvals and Trump are all on my watch list.

Biotech Premarket Movers: Amicus Therapeutics, Nantkwest and Organovo

Biotech Premarket Movers: Amicus Therapeutics, Nantkwest and Organovo

Amicus Therapeutics, Nantkwest and Organovo are among the premarket biotech movers on Tuesday.